OCUL
$8.68
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
Recent News
3 Reasons to Avoid OCUL and 1 Stock to Buy Instead
Shareholders of Ocular Therapeutix would probably like to forget the past six months even happened. The stock dropped 29.1% and now trades at $8.62. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
3 Stocks Under $10 We Think Twice About
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.
Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at pharmaceuticals stocks, starting with Ocular Therapeutix (NASDAQ:OCUL).
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock?
Relay Therapeutics (RLAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
3 Small-Cap Stocks We’re Skeptical Of
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.